
COVID-19 vaccines: The global dementia movement & how you can help
This 75-minute webinar will look at the ongoing development and distribution of COVID-19 vaccines and what this means for the global dementia community.
News, conferences, events, blogs and updates from across the field of dementia and the work of Alzheimer's Disease International.
This 75-minute webinar will look at the ongoing development and distribution of COVID-19 vaccines and what this means for the global dementia community.
This piece questioning how we see and understand dementia friendly communities, their role and how they may evolve was contributed to the World Alzheimer Report 2019 by Glenn Rees, Chair of ADI, and Dr Linda Barclay, a Senior Lecturer in Philosophy at Monash University who specialises in disability and justice.
Featured in the World Alzheimer Report 2019: Attitudes to dementia, María Cecilia López Murga, Executive of Asociación Group Ermita Alzheimer de Guatemala, writes about the sometimes difficulty in addressing dementia within Guatemala’s Indigenous communities and how Asociacion Group Ermita tries to address these challenges.
Featured in the World Alzheimer Report 2019: Attitudes to dementia, Kristen Jacklin, Professor of Medical Anthropology at the University of Minnesota Medical School Duluth and Karen Pitawanakwat, Registered Nurse and Community Researcher for Naandwechige-Gamig Wikwemikong Health Centre and member of the WikWemikong Unceded Reserve, write about the necessity in understanding the experiences of dementia within Indigenous communities in order to meet dementia care needs in a culturally sensitive way.
In 2016 Spominčica – Alzheimer Slovenija started developing the Dementia Friendly Spots (DFS) programme. It is a national education and awareness-raising programme connecting a wide spectrum of organisations in a network of sites providing information about dementia locally. The network of DFS include: police and fire stations, shops, libraries,…
hinese Pharmaceutical Company Green Valley announces their drug Oligomannate (GV-971) has been granted conditional approval for the treatment of "mild to moderate Alzheimer's disease".
Biogen and Eisai have announced they will file for market approval for an investigational treatment for early Alzheimer’s disease.
Ahead of the G20 Health Ministers Meeting in Okayama, ADI’s Chief Executive Paola Barbarino and Noriyo Washizu of Alzheimer's Association Japan (AAJ) continue to work on progress made earlier in the year at the Osaka Summit.
Ahead of the G20 Health Ministers Meeting in Okayama, ADI Chief Executive Paola was interviewed by one of Japan's largest newspaper.